M

Magle Chemoswed Holding AB
STO:MAGLE

Watchlist Manager
Magle Chemoswed Holding AB
STO:MAGLE
Watchlist
Price: 34 SEK
Market Cap: 667.4m SEK
Have any thoughts about
Magle Chemoswed Holding AB?
Write Note

Magle Chemoswed Holding AB
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Magle Chemoswed Holding AB
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
M
Magle Chemoswed Holding AB
STO:MAGLE
Total Liabilities & Equity
kr273m
CAGR 3-Years
11%
CAGR 5-Years
12%
CAGR 10-Years
N/A
AddLife AB
STO:ALIF B
Total Liabilities & Equity
kr12.7B
CAGR 3-Years
45%
CAGR 5-Years
37%
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Total Liabilities & Equity
kr6.1B
CAGR 3-Years
34%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotage AB
STO:BIOT
Total Liabilities & Equity
kr4.9B
CAGR 3-Years
48%
CAGR 5-Years
29%
CAGR 10-Years
23%
G
Genovis AB
STO:GENO
Total Liabilities & Equity
kr303.4m
CAGR 3-Years
42%
CAGR 5-Years
48%
CAGR 10-Years
25%
MedCap AB (publ)
STO:MCAP
Total Liabilities & Equity
kr1.9B
CAGR 3-Years
19%
CAGR 5-Years
19%
CAGR 10-Years
13%
No Stocks Found

Magle Chemoswed Holding AB
Glance View

Market Cap
667.4m SEK
Industry
Life Sciences Tools & Services

Magle Chemoswed Holding AB engages in the provision of contract development and manufacturing services to the pharmaceutical and medical device industry. The company is headquartered in Malmo, Skane. The company went IPO on 2020-06-30. The firm's operations are mainly conducted through the subsidiaries Magle Chemoswed AB and Adroit Science AB. The business is focused on process development and manufacturing of Active Pharmaceutical Ingredients (API) as well as research, development and manufacturing of products in the areas of wound care and diagnostics with particular focus on products based on degradables starch microspheres. Magle Chemoswed also functions as a consultancy in material characterization and solid phase analysis with a main focus on pharmaceutical companies.

MAGLE Intrinsic Value
85.47 SEK
Undervaluation 60%
Intrinsic Value
Price
M

See Also

What is Magle Chemoswed Holding AB's Total Liabilities & Equity?
Total Liabilities & Equity
273m SEK

Based on the financial report for Dec 31, 2023, Magle Chemoswed Holding AB's Total Liabilities & Equity amounts to 273m SEK.

What is Magle Chemoswed Holding AB's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
12%

Over the last year, the Total Liabilities & Equity growth was 8%. The average annual Total Liabilities & Equity growth rates for Magle Chemoswed Holding AB have been 11% over the past three years , 12% over the past five years .

Back to Top